spacer
spacer

PDBsum entry 1os5

Go to PDB code: 
protein ligands links
Transferase PDB id
1os5

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
563 a.a. *
Ligands
NH1
Waters ×560
* Residue conservation analysis
PDB id:
1os5
Name: Transferase
Title: Crystal structure of hcv ns5b RNA polymerase complexed with a novel non-competitive inhibitor.
Structure: Hepatitis c virus ns5b RNA polymerase. Chain: a. Engineered: yes. Mutation: yes
Source: Hepatitis c virus. Organism_taxid: 31647. Strain: subtype 1b. Gene: ns5b. Expressed in: escherichia coli. Expression_system_taxid: 562.
Resolution:
2.20Å     R-factor:   0.207     R-free:   0.251
Authors: R.A.Love,H.E.Parge,X.Yu,M.J.Hickey,W.Diehl,J.Gao,H.Wriggers,A.Ekker, L.Wang,J.A.Thomson,P.S.Dragovich,S.A.Fuhrman
Key ref: R.A.Love et al. (2003). Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J Virol, 77, 7575-7581. PubMed id: 12805457
Date:
18-Mar-03     Release date:   18-Mar-04    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P26663  (POLG_HCVBK) -  Genome polyprotein from Hepatitis C virus genotype 1b (isolate BK)
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
3010 a.a.
563 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 4 residue positions (black crosses)

 Enzyme reactions 
   Enzyme class 1: E.C.2.7.7.48  - RNA-directed Rna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: RNA(n) + a ribonucleoside 5'-triphosphate = RNA(n+1) + diphosphate
RNA(n)
+ ribonucleoside 5'-triphosphate
= RNA(n+1)
+ diphosphate
   Enzyme class 2: E.C.3.4.21.98  - hepacivirin.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Hydrolysis of four peptide bonds in the viral precursor polyprotein, commonly with Asp or Glu in the P6 position, Cys or Thr in P1 and Ser or Ala in P1'.
   Enzyme class 3: E.C.3.4.22.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 4: E.C.3.6.1.15  - nucleoside-triphosphate phosphatase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: a ribonucleoside 5'-triphosphate + H2O = a ribonucleoside 5'-diphosphate + phosphate + H+
ribonucleoside 5'-triphosphate
+ H2O
= ribonucleoside 5'-diphosphate
+ phosphate
+ H(+)
   Enzyme class 5: E.C.3.6.4.13  - Rna helicase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: ATP + H2O = ADP + phosphate + H+
ATP
+ H2O
= ADP
+ phosphate
+ H(+)
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
J Virol 77:7575-7581 (2003)
PubMed id: 12805457  
 
 
Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme.
R.A.Love, H.E.Parge, X.Yu, M.J.Hickey, W.Diehl, J.Gao, H.Wriggers, A.Ekker, L.Wang, J.A.Thomson, P.S.Dragovich, S.A.Fuhrman.
 
  ABSTRACT  
 
The virus-encoded nonstructural protein 5B (NS5B) of hepatitis C virus (HCV) is an RNA-dependent RNA polymerase and is absolutely required for replication of the virus. NS5B exhibits significant differences from cellular polymerases and therefore has become an attractive target for anti-HCV therapy. Using a high-throughput screen, we discovered a novel NS5B inhibitor that binds to the enzyme noncompetitively with respect to nucleotide substrates. Here we report the crystal structure of NS5B complexed with this small molecule inhibitor. Unexpectedly, the inhibitor is bound within a narrow cleft on the protein's surface in the "thumb" domain, about 30 A from the enzyme's catalytic center. The interaction between this inhibitor and NS5B occurs without dramatic changes to the structure of the protein, and sequence analysis suggests that the binding site is conserved across known HCV genotypes. Possible mechanisms of inhibition include perturbation of protein dynamics, interference with RNA binding, and disruption of enzyme oligomerization.
 

Literature references that cite this PDB file's key reference

  PubMed id Reference
  21235805 J.H.Lee, S.Lee, M.Y.Park, and H.Myung (2011).
Characterization of thiobarbituric acid derivatives as inhibitors of hepatitis C virus NS5B polymerase.
  Virol J, 8, 18.  
21490973 P.Clemente-Casares, A.J.López-Jiménez, I.Bellón-Echeverría, J.A.Encinar, E.Martínez-Alfaro, R.Pérez-Flores, and A.Mas (2011).
De novo polymerase activity and oligomerization of hepatitis C virus RNA-dependent RNA-polymerases from genotypes 1 to 5.
  PLoS One, 6, e18515.  
20071590 O.Nyanguile, B.Devogelaere, L.Vijgen, W.Van den Broeck, F.Pauwels, M.D.Cummings, H.L.De Bondt, A.M.Vos, J.M.Berke, O.Lenz, G.Vandercruyssen, K.Vermeiren, W.Mostmans, P.Dehertogh, F.Delouvroy, S.Vendeville, K.VanDyck, K.Dockx, E.Cleiren, P.Raboisson, K.A.Simmen, and G.C.Fanning (2010).
1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.
  J Virol, 84, 2923-2934.
PDB codes: 3hkw 3hky
21203539 R.C.Durk, K.Singh, C.A.Cornelison, D.K.Rai, K.B.Matzek, M.D.Leslie, E.Schafer, B.Marchand, A.Adedeji, E.Michailidis, C.A.Dorst, J.Moran, C.Pautler, L.L.Rodriguez, M.A.McIntosh, E.Rieder, and S.G.Sarafianos (2010).
Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase.
  PLoS One, 5, e15049.  
19075052 S.S.Carroll, S.Ludmerer, L.Handt, K.Koeplinger, N.R.Zhang, D.Graham, M.E.Davies, M.MacCoss, D.Hazuda, and D.B.Olsen (2009).
Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees.
  Antimicrob Agents Chemother, 53, 926-934.  
19307358 S.T.Shi, K.J.Herlihy, J.P.Graham, J.Nonomiya, S.V.Rahavendran, H.Skor, R.Irvine, S.Binford, J.Tatlock, H.Li, J.Gonzalez, A.Linton, A.K.Patick, and C.Lewis (2009).
Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
  Antimicrob Agents Chemother, 53, 2544-2552.  
18559648 A.Y.Howe, H.Cheng, S.Johann, S.Mullen, S.K.Chunduru, D.C.Young, J.Bard, R.Chopra, G.Krishnamurthy, T.Mansour, and J.O'Connell (2008).
Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
  Antimicrob Agents Chemother, 52, 3327-3338.  
18321230 G.Koev, and W.Kati (2008).
The emerging field of HCV drug resistance.
  Expert Opin Investig Drugs, 17, 303-319.  
18694956 K.J.Herlihy, J.P.Graham, R.Kumpf, A.K.Patick, R.Duggal, and S.T.Shi (2008).
Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
  Antimicrob Agents Chemother, 52, 3523-3531.  
  18268843 K.K.Ng, J.J.Arnold, and C.E.Cameron (2008).
Structure-function relationships among RNA-dependent RNA polymerases.
  Curr Top Microbiol Immunol, 320, 137-156.  
18667512 M.Hass, M.Lelke, C.Busch, B.Becker-Ziaja, and S.Günther (2008).
Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome.
  J Virol, 82, 10207-10217.  
18054491 M.Mazzei, E.Nieddu, M.Miele, A.Balbi, M.Ferrone, M.Fermeglia, M.T.Mazzei, S.Pricl, P.La Colla, F.Marongiu, C.Ibba, and R.Loddo (2008).
Activity of Mannich bases of 7-hydroxycoumarin against Flaviviridae.
  Bioorg Med Chem, 16, 2591-2605.  
18203743 N.Kaushik-Basu, A.Bopda-Waffo, T.T.Talele, A.Basu, P.R.Costa, A.J.da Silva, S.G.Sarafianos, and F.Noël (2008).
Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors.
  Nucleic Acids Res, 36, 1482-1496.  
18070954 S.T.Shi, K.J.Herlihy, J.P.Graham, S.A.Fuhrman, C.Doan, H.Parge, M.Hickey, J.Gao, X.Yu, F.Chau, J.Gonzalez, H.Li, C.Lewis, A.K.Patick, and R.Duggal (2008).
In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase.
  Antimicrob Agents Chemother, 52, 675-683.  
18049474 E.De Clercq (2007).
The design of drugs for HIV and HCV.
  Nat Rev Drug Discov, 6, 1001-1018.  
17600342 F.Fernandes, D.S.Poole, S.Hoover, R.Middleton, A.C.Andrei, J.Gerstner, and R.Striker (2007).
Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.
  Hepatology, 46, 1026-1033.  
17459932 F.Pauwels, W.Mostmans, L.M.Quirynen, L.van der Helm, C.W.Boutton, A.S.Rueff, E.Cleiren, P.Raboisson, D.Surleraux, O.Nyanguile, and K.A.Simmen (2007).
Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors.
  J Virol, 81, 6909-6919.  
17060518 W.Hao, K.J.Herlihy, N.J.Zhang, S.A.Fuhrman, C.Doan, A.K.Patick, and R.Duggal (2007).
Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.
  Antimicrob Agents Chemother, 51, 95.  
16940072 A.Y.Howe, H.Cheng, I.Thompson, S.K.Chunduru, S.Herrmann, J.O'Connell, A.Agarwal, R.Chopra, and A.M.Del Vecchio (2006).
Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.
  Antimicrob Agents Chemother, 50, 4103-4113.  
16699182 D.E.Danley (2006).
Crystallization to obtain protein-ligand complexes for structure-aided drug design.
  Acta Crystallogr D Biol Crystallogr, 62, 569-575.  
16719717 J.Ortín, and F.Parra (2006).
Structure and function of RNA replication.
  Annu Rev Microbiol, 60, 305-326.  
16731953 S.Le Pogam, H.Kang, S.F.Harris, V.Leveque, A.M.Giannetti, S.Ali, W.R.Jiang, S.Rajyaguru, G.Tavares, C.Oshiro, T.Hendricks, K.Klumpp, J.Symons, M.F.Browner, N.Cammack, and I.Nájera (2006).
Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
  J Virol, 80, 6146-6154.
PDB codes: 2giq 2gir
15661135 H.Ma, V.Leveque, A.De Witte, W.Li, T.Hendricks, S.M.Clausen, N.Cammack, and K.Klumpp (2005).
Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.
  Virology, 332, 8.  
16189112 H.Mo, L.Lu, T.Pilot-Matias, R.Pithawalla, R.Mondal, S.Masse, T.Dekhtyar, T.Ng, G.Koev, V.Stoll, K.D.Stewart, J.Pratt, P.Donner, T.Rockway, C.Maring, and A.Molla (2005).
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
  Antimicrob Agents Chemother, 49, 4305-4314.  
15855531 J.E.Tomassini, K.Getty, M.W.Stahlhut, S.Shim, B.Bhat, A.B.Eldrup, T.P.Prakash, S.S.Carroll, O.Flores, M.MacCoss, D.R.McMasters, G.Migliaccio, and D.B.Olsen (2005).
Inhibitory effect of 2'-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells.
  Antimicrob Agents Chemother, 49, 2050-2058.  
16107835 R.De Francesco, and G.Migliaccio (2005).
Challenges and successes in developing new therapies for hepatitis C.
  Nature, 436, 953-960.  
15855532 S.W.Ludmerer, D.J.Graham, E.Boots, E.M.Murray, A.Simcoe, E.J.Markel, J.A.Grobler, O.A.Flores, D.B.Olsen, D.J.Hazuda, and R.L.LaFemina (2005).
Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.
  Antimicrob Agents Chemother, 49, 2059-2069.  
14739234 G.McKercher, P.L.Beaulieu, D.Lamarre, S.LaPlante, S.Lefebvre, C.Pellerin, L.Thauvette, and G.Kukolj (2004).
Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate.
  Nucleic Acids Res, 32, 422-431.  
14694125 L.Tomei, S.Altamura, L.Bartholomew, M.Bisbocci, C.Bailey, M.Bosserman, A.Cellucci, E.Forte, I.Incitti, L.Orsatti, U.Koch, R.De Francesco, D.B.Olsen, S.S.Carroll, and G.Migliaccio (2004).
Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.
  J Virol, 78, 938-946.  
15296746 R.A.Love, K.A.Maegley, X.Yu, R.A.Ferre, L.K.Lingardo, W.Diehl, H.E.Parge, P.S.Dragovich, and S.A.Fuhrman (2004).
The crystal structure of the RNA-dependent RNA polymerase from human rhinovirus: a dual function target for common cold antiviral therapy.
  Structure, 12, 1533-1544.
PDB codes: 1te8 1te9 1teb 1xr5 1xr6 1xr7
15268625 V.Brass, H.E.Blum, and D.Moradpour (2004).
Recent developments in target identification against hepatitis C virus.
  Expert Opin Ther Targets, 8, 295-307.  
14645579 L.Tomei, S.Altamura, L.Bartholomew, A.Biroccio, A.Ceccacci, L.Pacini, F.Narjes, N.Gennari, M.Bisbocci, I.Incitti, L.Orsatti, S.Harper, I.Stansfield, M.Rowley, R.De Francesco, and G.Migliaccio (2003).
Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
  J Virol, 77, 13225-13231.  
14654687 X.Xu, Y.Liu, S.Weiss, E.Arnold, S.G.Sarafianos, and J.Ding (2003).
Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design.
  Nucleic Acids Res, 31, 7117-7130.
PDB code: 1o5s
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.

 

spacer

spacer